Contact your GP or prescribing clinician before combining these medications if you: Have a history of peptic ulcer disease, gastritis, or gastrointestinal bleeding Have cardiovascular disease, including heart failure, ischaemic heart disease, or poorly controlled hypertension Have kidney disease or impaired renal function Are taking multiple medications, particularly anticoagulants (such as warfarin or DOACs), corticosteroids, SSRIs, or other medications that increase bleeding risk Are over 65 years of age, as the risk of NSAID-related complications increases with age Have experienced severe or persistent gastrointestinal side effects from Saxenda Require regular or long-term NSAID use for chronic pain conditions Seek urgent medical attention if you experience: Black, tarry stools or blood in vomit (potential signs of gastrointestinal bleeding) Severe, persistent abdominal pain that differs from typical Saxenda-related discomfort, especially if radiating to the back or accompanied by vomiting (stop taking Saxenda immediately due to pancreatitis risk) Symptoms of dehydration including dizziness, reduced urination, or extreme thirst, particularly if experiencing vomiting or diarrhoea Chest pain, shortness of breath, or signs of allergic reaction (rash, swelling, difficulty breathing) Significant changes in urination or signs of kidney problems (swelling in legs or ankles, fatigue) For routine medication reviews, ensure you inform all healthcare professionals about your complete medication list, including prescription medications, over-the-counter products, and supplements
The vial touches it
Experimental weight loss drug retatrutide shows dramatic weight loss in clinical trial Amid the growing demand for GLP-1 medications for weight loss, a new experimental drug, retatrutide, stands out, according to new clinical trial results released on Thursday
Most patients will want to use it for four months, and if its successful, you may want to continue its use
95% CI: 1.081.32), emphasizing the importance of personalized approaches based on individual risk factors (48)
Some researchers are interested in whether GLP-1 receptor agonists could have lasting effects on brain function
